Participants in the study will take the medication NPI-001 orally for a period of up to 12 months. During this time, they will have regular check-ups to monitor their health and any side effects. The study will also look at how often brain bleeding events occur in patients taking the medication. This will help researchers understand if the treatment can reduce these events and improve the condition.

Throughout the study, participants will undergo various assessments, including blood tests, skin biopsies, and MRI scans of the brain. These tests will help track changes in the body and the effects of the treatment. The study aims to provide valuable information on the potential benefits of NPI-001 for people with Hereditary Cystatin C Amyloid Angiopathy.

The purpose of this study is to compare two different lengths of treatment with esomeprazole to see if a shorter treatment period works as well as a longer one in reducing dyspepsia symptoms. Some people in the study will take esomeprazole for seven days, while others will take it for four weeks. The study will measure changes in symptoms using a scoring system called the Glasgow Dyspepsia Severity Score, which tracks how severe the symptoms are over time. The study aims to determine whether the shorter treatment is not worse than the longer treatment, meaning it provides similar relief.

During the study, participants will take esomeprazole by mouth according to their assigned treatment schedule. They will record their symptoms daily so that researchers can track any changes. The maximum daily dose of esomeprazole will be 40 milligrams, and participants may use Rennie as needed for additional symptom relief. The study will last for several weeks, during which time participants will continue to monitor their symptoms. If symptoms do not improve or worsen, participants may be referred for an upper gastrointestinal endoscopy, which is a procedure that allows doctors to look inside the stomach and upper digestive tract using a thin tube with a camera.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of this research is to evaluate how safe the medication is and how well patients tolerate it when used for a longer period. The medication is given as a subcutaneous injection (under the skin) using a pre-filled syringe. This is an open-label extension study, which means all participants will receive the actual medication, and it continues treatment for patients who completed an earlier study called Lp(a)HORIZON.

During the study, participants will receive regular doses of pelacarsen for up to 36 months. The maximum daily dose is 80 milligrams. The study will monitor participants’ health through regular check-ups and blood tests to ensure their safety while taking the medication. Researchers will track various health measurements and any side effects that may occur during the treatment period.

Participants in the study will be randomly assigned to receive either the NPI-001 tablet or a placebo, which looks like the real medication but does not contain the active ingredient. The study will last for up to 12 months, during which participants will have regular check-ups and tests, including MRI scans to monitor changes in the brain. These tests will help researchers understand how the treatment affects the brain and whether it can reduce harmful substances associated with Alzheimer’s Disease.

The study will also involve blood tests to measure changes in specific proteins and other markers related to Alzheimer’s Disease. Participants will be monitored for any side effects or changes in their health throughout the study. This research aims to provide valuable information about the potential benefits and risks of NPI-001 for people living with Alzheimer’s Disease.

Participants in the study will be randomly assigned to receive either Saroglitazar Magnesium or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about 52 weeks, during which participants will take the medication once daily. Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The main goal is to see if Saroglitazar Magnesium can improve certain liver function tests, specifically the levels of alkaline phosphatase (ALP) and bilirubin, which are indicators of liver health.

By the end of the study, researchers hope to determine if Saroglitazar Magnesium is more effective than the placebo in improving liver function in people with PBC. This information could help in developing better treatments for those living with this chronic liver disease.

Participants in the study will be divided into groups based on their risk level. Those with high-risk disease will receive all three medications: rituximab, lenalidomide, and tafasitamab. Those with low-risk disease will receive rituximab and lenalidomide, with a chance of also receiving tafasitamab. The study will follow participants over a period to observe the effects of these treatments on their condition.

The trial aims to understand how these medications work together to treat follicular lymphoma and to monitor any side effects that may occur. The study will also look at how long the treatment effects last and how they impact the overall health and quality of life of the participants. This research is important for developing better treatment strategies for people with follicular lymphoma.

The study uses a platform design, which means it can evaluate multiple treatments at the same time. Patients will receive one or more of the study medications depending on their specific medical needs. The treatments will be given for up to 90 days while patients are in the intensive care unit.

The study will track various outcomes to determine how well the treatments work, including how long patients survive, how many days they spend without needing life support machines, how many days they spend out of the hospital, and their quality of life after treatment. The study will also monitor patients for any side effects from the medications.

The purpose of the study is to determine if pelacarsen can reduce the risk of major heart-related events, such as heart attacks, strokes, and the need for urgent heart procedures, in people who already have cardiovascular disease. Participants in the study will receive either the pelacarsen treatment or a placebo. The study will monitor participants over a period to see how the treatment affects their health and the occurrence of these major events.

Throughout the study, participants will receive regular injections and will be closely monitored by healthcare professionals. The study will help researchers understand if lowering lipoprotein (a) with pelacarsen can provide significant benefits for people with cardiovascular disease. The results could lead to new treatment options for managing heart health in the future.

The purpose of the study is to evaluate how well these treatments work in achieving a state called MRD negativity, which means no minimal residual disease is detected, three years after starting the treatment. Patients with intermediate-risk smoldering multiple myeloma will receive a combination of dexamethasone and lenalidomide, while those with high-risk smoldering multiple myeloma will receive all three medications: dexamethasone, lenalidomide, and carfilzomib. The study will also look at the safety of these treatments and their overall effects on the disease.

Participants in the study will follow a treatment plan over a period of time, with regular check-ups to monitor their health and the progress of the disease. The study aims to provide valuable information on the effectiveness of these treatments in managing multiple myeloma and improving patient outcomes. The trial is expected to continue until 2027, with the goal of better understanding how these medications can help patients with this condition.

The purpose of this study is to determine if the chemoablation treatment with Mitomycin is more effective in the long term compared to the standard TURBT procedure with BCG therapy. Participants in the study will be randomly assigned to receive either the Mitomycin treatment or the TURBT procedure with BCG. The study will monitor the participants over a period of time to see how well each treatment works in preventing the cancer from coming back.

Throughout the study, participants will receive regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on which treatment option offers better outcomes for patients with recurrent non-muscle invasive bladder cancer. This research could help improve future treatment strategies for this type of cancer.

Participants in the study will apply the MOB015B solution to the affected toenail over a period of time. The study will monitor the progress of the treatment to see if it leads to a reduction in the infection and ultimately a cure. The trial will also assess the safety of the treatment to ensure it is well-tolerated by the participants. The study aims to achieve treatment success, which is defined as a significant reduction in the infection and a cure of the affected toenail.

The trial will take place over several months, with regular check-ins to monitor the condition of the toenail and the overall health of the participants. The study will conclude with an evaluation of the treatment’s effectiveness and safety, providing valuable information on the use of MOB015B for treating distal subungual onychomycosis in children. Participants will be closely observed to ensure their well-being throughout the study period.

The purpose of the study is to see how well JDQ443 works compared to docetaxel in controlling the cancer. Participants will receive either JDQ443 in tablet form or docetaxel through an intravenous infusion, which means it is given directly into a vein. Some participants may also receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will monitor how long the cancer stays under control and will also look at overall survival rates, which means how long participants live after starting the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and any side effects they might experience. The study will also collect information on how the treatments affect symptoms like chest pain, coughing, and shortness of breath. The trial is expected to continue until the end of 2025, and the results will help determine if JDQ443 is a better option for treating this type of lung cancer compared to the current standard treatment with docetaxel.

The purpose of the study is to assess how well patients achieve remission, which means a reduction or disappearance of symptoms, with these treatments. The study will also explore two different strategies for reducing the dosage of medication in patients who respond well to the initial treatment. Participants will be randomly assigned to receive either conventional therapy or one of the biologic treatments. The study will monitor the participants over a period to see how their condition improves and whether they can maintain remission with reduced medication.

Throughout the study, participants will receive regular assessments to track their progress. These assessments will help determine the effectiveness of the treatments and the best approach for managing Rheumatoid Arthritis. The study is designed to provide valuable information on how different treatments can help patients achieve and maintain remission, ultimately improving their quality of life.

The purpose of the study is to assess how Aficamten affects the health status and exercise capacity of participants with this heart condition. Participants will be randomly assigned to receive either Aficamten or a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure the results are unbiased. The trial will last for a period of 72 weeks, during which participants will undergo regular assessments to monitor their health and response to the treatment.

Throughout the study, participants will have their exercise capacity measured, which involves evaluating how well they can perform physical activities. The study will also monitor changes in their heart condition and overall health. The goal is to determine if Aficamten can improve symptoms and quality of life for those living with symptomatic non-obstructive hypertrophic cardiomyopathy. This research could potentially lead to new treatment options for individuals affected by this heart condition.

Participants in the study will be randomly assigned to receive either olaparib or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not biased. The treatment will be given in the form of film-coated tablets, which are taken by mouth.

The study will last for a period of up to 12 months, during which time the participants will be monitored for their health and any changes in their condition. The main goal is to assess the “Invasive Disease Free Survival” (IDFS), which means the length of time the patients remain free from cancer that has spread or returned. Other aspects, such as overall survival and the occurrence of new cancers, will also be observed. The study aims to provide valuable information on the safety and effectiveness of olaparib as an additional treatment for this type of breast cancer.

The study aims to determine if evolocumab can reduce the risk of death from coronary heart disease, heart attacks, and strokes in people receiving standard cholesterol-lowering therapy. The medication is given as an injection under the skin using a pre-filled pen that contains 140 mg of evolocumab.

During the study, participants will receive either evolocumab injections or placebo injections. The treatment period lasts for 72 weeks, during which participants will continue their usual cholesterol-lowering medications. The study will track various heart-related health events, including arterial revascularization (procedures to restore blood flow in blocked arteries) and death from heart-related causes.

Participants in the study will be randomly assigned to either continue with rituximab treatment or to discontinue it. The study will monitor the participants over a period of time to observe any changes in their condition, particularly focusing on whether the disease comes back. The study will also look at other factors such as kidney function, overall health quality, and any side effects experienced during the trial.

The trial aims to provide valuable information on the best approach to managing ANCA-associated vasculitis in patients who are in stable remission. By understanding the effects of continuing or stopping rituximab, the study hopes to improve treatment strategies for this condition.

The purpose of the study is to see if providing luteal phase support with vaginal progesterone is better than not providing any support, in terms of achieving a live birth. If it is found to be beneficial, the study will also compare whether a 7-week treatment is more effective than a 3-week treatment. Participants in the study will receive either the progesterone treatment or a placebo, and their progress will be monitored over time to assess various outcomes related to pregnancy and birth.

Throughout the study, researchers will track several outcomes, including live birth rates, pregnancy progression, and any complications that may arise during pregnancy. The study will also look at the cost-effectiveness of the treatment and measure progesterone levels in blood samples. The trial is expected to continue until early 2026, with the goal of providing valuable insights into the effectiveness of vaginal progesterone in supporting successful pregnancies for those experiencing infertility.

The study will test inclisiran, given as an injection under the skin, against placebo while participants continue taking their usual cholesterol-lowering medications. These medications include either atorvastatin (40 mg daily) or rosuvastatin (20 mg or more daily), which belong to a group of drugs called statins that help lower cholesterol levels in the blood.

During the study, which will last for 72 months, participants will receive regular injections of either inclisiran or placebo along with their daily statin medication. The researchers will monitor participants to see if the combination of treatments helps prevent serious cardiovascular events like heart attacks and strokes.

Participants in the study will take Aficamten in the form of a film-coated tablet, which is taken orally. The study will monitor patients over a period to observe any side effects or changes in their condition. The study aims to ensure that Aficamten is safe for long-term use and to understand how it affects the heart’s function in people with HCM. The study will also compare the effects of Aficamten with a placebo to determine its effectiveness.

Throughout the study, researchers will keep track of any adverse events, which are any unwanted effects that occur during the trial. They will also monitor the heart’s performance, specifically looking at the heart’s ability to pump blood effectively. This will help determine if Aficamten can be a safe and effective treatment option for people living with symptomatic HCM. The study is designed to provide valuable insights into the management of this heart condition and improve treatment options for patients in the future.

The purpose of this study is to improve the overall event-free survival for children and adolescents who have been newly diagnosed with AML. The study will explore whether adding Gemtuzumab Ozogamicin to the first course of treatment can enhance early anti-leukemic effects in patients with a specific type of AML known as CD33-positive. Additionally, the study will compare the effectiveness of two versus three courses of consolidation therapy, which is a phase of treatment aimed at maintaining remission, in patients who are considered to be at standard risk.

Participants in the study will receive different combinations of the medications mentioned above, depending on their specific treatment plan. The study will monitor the participants’ response to the treatment over time, focusing on their event-free survival, which refers to the length of time they remain free from certain complications or events related to their disease. The study will also assess the safety and side effects of the treatments. The trial is expected to continue until 2036, with recruitment having started in August 2023.

The purpose of the study is to find out if combining radiation therapy with durvalumab and chemotherapy can improve the survival rate of patients with this type of lung cancer. Participants in the study will receive these treatments, and some may receive a placebo instead of the active medication. The study will monitor the participants over time to see how well the treatments work and to check for any side effects. The study aims to understand the benefits of this combined treatment approach over a period of several years.

Throughout the study, researchers will look at various outcomes, such as how long patients live after starting the treatment and how the cancer responds to the treatment. They will also assess the quality of life of the participants and any side effects they experience. This information will help determine if the addition of radiation therapy to the existing treatment plan can provide a significant benefit to patients with extensive stage small-cell lung cancer.

The purpose of the study is to evaluate the safety and effectiveness of Quizartinib in treating this specific type of AML. Participants will receive up to two courses of chemotherapy along with Quizartinib. The study will monitor how well the treatment works by checking if the cancer cells are reduced to very low levels in the bone marrow. This is done using a method called flow cytometry, which helps in measuring the number of cancer cells. The study will also assess the safety of Quizartinib by observing any side effects that occur during the treatment period.

Throughout the study, participants will be evaluated at different stages to see how their bodies respond to the treatment. This includes checking for any adverse effects and measuring the levels of cancer cells in the bone marrow. The study aims to find the most suitable dose of Quizartinib that can be safely given to children and adolescents with this type of AML. The overall goal is to improve treatment outcomes for young patients with this challenging form of leukemia.

Participants in the study will be given Apixaban, which is a type of medication known as an anticoagulant. Anticoagulants help prevent blood clots, which can lead to strokes. The study will compare the effects of taking Apixaban with not taking any anticoagulant medication. Some participants may receive a placebo, which looks like the medication but does not contain any active ingredients. The study will last for a period of up to 72 weeks, during which participants will take the medication orally, meaning they will swallow it in the form of a tablet.

The main goal is to determine if Apixaban can reduce the risk of having an ischemic stroke, which is a type of stroke caused by a blood clot blocking a blood vessel in the brain, or systemic embolism, which is when a blood clot travels to other parts of the body. The study will also monitor for any serious side effects, such as bleeding in the brain or other major bleeding events. Participants will be closely monitored throughout the study to ensure their safety and to gather information on the effectiveness of the treatment.

The purpose of the study is to determine if Secukinumab, when combined with a glucocorticoid taper regimen, is more effective than a placebo in helping patients with PMR achieve sustained remission, which means the symptoms of the disease are reduced or disappear for a period of time. The study will last for up to 52 weeks, during which participants will be monitored to see how well they respond to the treatment. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to assess their health and the effectiveness of the treatment. The main goal is to see how many participants achieve sustained remission by the end of the study. Additionally, the study will look at the overall safety and tolerability of the treatment, including any side effects that may occur. This research aims to provide valuable information on the potential benefits of Secukinumab for people with Polymyalgia Rheumatica.

The study involves a series of once-weekly treatments for six weeks, followed by maintenance therapy for 12 months. The researchers aim to understand how this new schedule affects side effects, how well patients can stick to the treatment plan, and the overall outcomes related to cancer. Participants will receive a total of six initial treatments, and then continue with maintenance treatments over the course of a year.

Throughout the study, the researchers will monitor various outcomes, such as the recurrence of cancer, progression of the disease, and survival rates over two and five years. They will also track the number of treatments each participant receives and any side effects experienced. This information will help determine if the new treatment schedule is effective and safe for patients with high-risk non-muscle invasive bladder cancer (NMIBC).

The purpose of the study is to see how safe and well-tolerated NPI-001 is for patients with HCCAA. Researchers will also look at how effective the treatment is in reducing the frequency of brain bleeding events compared to past rates. Additionally, the study will examine changes in certain proteins and markers in the skin, which are related to the disease, using advanced techniques.

Participants in the study will take the medication for up to 12 months. During this time, they will have regular check-ups, including skin biopsies and blood tests, to monitor their health and the effects of the treatment. The study will also involve MRI scans of the brain to assess any changes. The goal is to gather information that could help improve the understanding and management of HCCAA in the future.

The purpose of the study is to test these treatments in a structured way to see how well they work and to gather information about their effects. The study will involve different phases where participants will receive these treatments over a period of time. The treatments will be given in various forms, such as oral suspensions, tablets, or injections, depending on the specific medication. The study will also explore the potential benefits of new types of treatments, such as immunotherapy, for certain groups of patients.

Throughout the study, participants will be monitored to assess the effectiveness of the treatments and to identify any side effects. The study will collect data on survival rates, the occurrence of any relapses, and the overall quality of life of the participants. This information will help researchers understand how these treatments can be used to improve outcomes for people with Acute Lymphoblastic Leukemia.

Participants in the study will be randomly assigned to receive either the dual therapy of ticagrelor and aspirin or aspirin alone. The study will monitor the participants over a period of 12 months to observe the occurrence of major adverse cardiovascular events, which include serious issues like heart attacks, strokes, or the need for additional heart procedures. The study aims to see if the combination of medications can reduce these events compared to using aspirin alone.

The trial will help to understand whether adding ticagrelor to the standard aspirin treatment can provide better protection against heart-related complications after surgery. This research is important for improving treatment strategies for patients with acute coronary syndrome who have undergone CABG, potentially leading to better long-term health outcomes.